<DOC>
	<DOCNO>NCT01211678</DOCNO>
	<brief_summary>The primary objective study validate ability 8-gene biomarker set differentiate participant meet meet European League Against Rheumatism ( EULAR ) Disease Activity Score ( DAS ) -28 Good Response criterion treatment anti-Tumor Necrosis Factor ( TNF ) therapy 14 week approximately 200 anti-TNF-naïve participant . The secondary objective study ( ) compare behavior 8-gene marker set participant anti-TNF naïve versus begin second anti-TNF treatment , ( ii ) develop , maintain , utilize biorepository serum , plasma , RNA , deoxyribonucleic acid ( DNA ) sample additional experiment analysis ( iii ) discover novel genetic ( DNA ) predictor response anti-TNF therapy .</brief_summary>
	<brief_title>Biomarkers Anti-TNF-α Therapy Efficacy Rheumatoid Arthritis Define Unresponsive Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Inclusion Criteria To eligible participate study , candidate must meet following eligibility criterion time enrollment : Are willing able provide inform consent.. Meet ACR criterion RA determine rheumatologist board certify Rheumatology member ACR . Have 4 tender 4 swollen joint 28 joint assess treat rheumatologist train joint assessor . Subjects take follow treatment and/or wash minimum duration define . If subject currently take treatment , must stable dose regimen minimum duration define : Oral DMARDs ( MTX , hydroxychloroquine , sulfasalazine , leflunomide , cyclosporine , azathioprine ) : drug least 3 month wash stable least 6 week prior baseline sample collection . Oral corticosteroid : wash stable AND ≤10 mg/day prednisone equivalent least 4 week prior baseline sample collection . Intraarticular parenteral corticosteroid : Washed stable least 4 week prior baseline sample collection . NSAIDs : Washed stable least 2 week prior baseline sample collection . Are start treatment antiTNF agent approve treatment RA first time OR Have , opinion treat rheumatologist , achieve maintained adequate response treatment first antiTNF agent ( antiTNF agent approve treatment RA ) , prescribe different anti TNF agent . Subjects switch reason lack efficacy exclude . Key Exclusion Criteria Candidates exclude study entry follow exclusion criterion exist time enrollment : Any medical condition would preclude safe use antiTNF agent least 14 week . Previous participation present study subject antiTNFnaïve group . Prior exposure 2 antiTNF agent . Prior exposure Orencia ( abatacept , CTLA4Ig ) and/or Rituxan ( anti CD20 ) , biologic therapy RA diseases . Note : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>